Biochemical Efficacy and Safety of a New, Ready-to-Use, Liquid Alpha-1-Proteinase Inhibitor, GLASSIA (Alpha₁-Proteinase Inhibitor (Human), Intravenous)

References

• Eriksson S. Alpha1-antitrypsin deficiency: lessons learned from the bedside to the gene and back again. Chest 1989; 95:181–189.
   PubMed Web of Science ®Google Scholar
• Tobin MJ, Cook PJ, Hutchinson DC. Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in patients homozygous for Pi type Z. A survey by the British Thoracic Association. Br J Dis Chest 1983; 77(1):14–27.
   PubMedGoogle Scholar
• American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003; 168:818–900.
   PubMed Web of Science ®Google Scholar
• Cole RB, Nevin NC, Blundell G, Relation of alpha-1-antitrypsin phenotype to the performance of pulmonary function tests and to the prevalence of respiratory illness in a working population. Thorax 1976; 31(2):149–157.
   PubMed Web of Science ®Google Scholar
• Petrache I, Fijalkowska I, Zhen L, A novel antiapoptotic role for alpha-1antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med 2006; 173:1222–1228.
   PubMed Web of Science ®Google Scholar
• Sandhaus RA. Elastase may play a central role in the neutrophil migration through connective tissue. In: Taylor JC, Mittman C, eds. Pulmonary emphysema and proteolysis. Orlando, FL: Academic Press, 1997:227–233.
   Google Scholar
• de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002; 122(5): 1818–1829.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Alpha-1-antitrypsin deficiency. Memorandum from a WHO meeting. Bull WHO 1997; 75:397–415.
   PubMed Web of Science ®Google Scholar
• Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011; 5:391–405.
   PubMed Web of Science ®Google Scholar
• Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365(9478):2225–2236.
   PubMed Web of Science ®Google Scholar
• Stolk J, Seersholm N, Kalsheker N. Alpha-1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J COPD 2006; 1(2):151–160.
   Google Scholar
• Silverman EK, Sandhaus RA. Clinical practice. Alpha1-antitrypsin deficiency. N Engl J Med 2009 Jun 25; 360(26):2749–2757.
   PubMed Web of Science ®Google Scholar
• Sandhaus RA. Augmentation therapy in alpha-1 antitrypsin deficiency. COPD J 2009 Jun; 6(3):147–148.
   PubMedGoogle Scholar
• Petrache I, Hajjar J, Campos M. Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency. Biologics 2009; 3:193–204.
   PubMedGoogle Scholar
• Wewers MD, Casolaro MA, Sellers SE, Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316(17):1055–1062.
   PubMed Web of Science ®Google Scholar
• Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD J 2009 Jun; 6(3):177–184.
   PubMedGoogle Scholar
• Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Respir Res 2010 Oct 5; 11:136.
   PubMed Web of Science ®Google Scholar
• Tonelli AR, Rouhani F, Li N, Schreck P, Brantly ML. Alpha-1-antitrypsin augmentation therapy in deficient individuals enrolled in the Alpha-1 Foundation DNA and Tissue Bank. Int J Chron Obstruct Pulmon Dis 2009; 4:443–452.
   PubMedGoogle Scholar
• Sandhaus RA. Alpha-1 antitrypsin deficiency: whom to test, whom to treat? Semin Respir Crit Care Med 2010 Jun; 31(3):343–347.
   PubMed Web of Science ®Google Scholar
• Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010a Jul 7; (7): CD007851.
   Web of Science ®Google Scholar
• Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Dan Med Bull 2010b Sep; 57(9):A4175.
   PubMedGoogle Scholar
• Russi EW. Alpha-1 antitrypsin: now available, but do we need it? Swiss Med Wkly 2008; 138(13–14):191–196.
   PubMed Web of Science ®Google Scholar
• Abboud RT, Ford GT, Chapman KR; Standards Committee of the Canadian Thoracic Society. Alpha1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J 2001; 8(2):81–88.
   PubMedGoogle Scholar
• ARALAST NP Prescribing Information. Baxter Healthcare Corporation. Westlakes Village, CA, 2010. http://www.baxter.com/downloads/healthcare_professionals/products/Aralast_NP_PI.pdf
   Google Scholar
• Stocks JM, Brantly ML, Wang-Smith L, Campos MA, Chapman KR, Kueppers F, Pharmacokinetic comparability of ROLASTIN®-C to PROLASTIN® in alpha1-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol 2010; 10:13.
   PubMedGoogle Scholar
• Stoller JK, Rouhani F, Brantly M, Biochemical efficacy and safety of a new pooled human plasma alpha(1)-antitrypsin, Respitin. Chest 2002; 122:66–74.
   PubMed Web of Science ®Google Scholar
• Louie SG, Sclar DA, Gill MA. ARALAST: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Ann Pharmacother 2005; 39(11):1861–1869.
   PubMed Web of Science ®Google Scholar
• Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, Donohue JF, Sandhaus R. Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD J 2006; 3:17–23.
   PubMedGoogle Scholar
• Healthcare Providers. Augmentation Therapy. http://www.alpha-1foundation.org/healthcare/?c = 03a-Augmentation-Therapy. Accessed 3/15/2012.
   Google Scholar
• Luisetti M, Miravitlles M, Stockley RA. α-1-antitrypsin deficiency: a report from the 2nd meeting of the Alpha One International Registry, Rapallo (Genoa, Italy), 2001. Eur Respir J 2002; 20:1050–1056.
   PubMedGoogle Scholar
• Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events. Chest 2003 May; 123(5):1425–1434.
   PubMed Web of Science ®Google Scholar
• Stoller JK, Aboussouan LS. alpha1-Antitrypsin deficiency. 5: intravenous augmentation therapy: current understanding. Thorax 2004 Aug; 59(8):708–712.
   PubMed Web of Science ®Google Scholar